Caris & Company Slaps A "Sell" On Auxilium Pharmaceuticals (AUXL)
More News related to AUXL
- Bank of America Resumes Coverage on Auxilium Pharmaceuticals (AUXL) with a Buy
- Auxilium Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
- Auxilium Pharmaceuticals to Present at the Credit Suisse 18th Annual Global Healthcare Conference
- Auxilium Pharmaceuticals, Inc. (AUXL) Chief Executive Officer and President to Ring The NASDAQ Stock Market Closing Bell
- Auxilium Pharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare Conference
Caris & Company initiated coverage on Auxilium Pharmaceuticals Inc. (Nasdaq: AUXL) with a Sell rating and $18 downside price target.
Caris & Co's price target represents 39% downside from the current price of $29.39.
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing and marketing products to urologists, endocrinologists, orthopedists, and primary care physicians primarily in the United States.
Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php
Related Categories
New CoverageStocks Mentioned
-0.29Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
